The PE Ratio as of December 2024 (TTM) for ADMA Biologics, Inc. (ADMA) is 65.63

According to ADMA Biologics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 65.63. This represents a change of 336.65% compared to the average of 15.03 of the last 4 quarters.

ADMA Biologics, Inc. (ADMA) Historical PE Ratio (quarterly & annually)

How has ADMA PE Ratio performed in the past?

The mean historical PE Ratio of ADMA Biologics, Inc. over the last ten years is -7.03. The current 65.63 PE Ratio has changed -93480.87% with respect to the historical average. Over the past ten years (40 quarters), ADMA's PE Ratio was at its highest in in the September 2023 quarter at 78.60. The PE Ratio was at its lowest in in the June 2023 quarter at -32.25.

ADMA Biologics, Inc. (ADMA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of ADMA Biologics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

ADMA Biologics, Inc. (ADMA) Average PE Ratio

How has ADMA PE Ratio performed in the past?

The current PE Ratio of ADMA Biologics, Inc. (ADMA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

ADMA Biologics, Inc. (ADMA) PE Ratio vs. Peers

How is ADMA’s PE Ratio compared to its peers?

ADMA Biologics, Inc.’s PE Ratio is greater than Atara Biotherapeutics, Inc. (-0.09), greater than Fate Therapeutics, Inc. (-1.10), greater than Sana Biotechnology, Inc. (-1.25), greater than Caribou Biosciences, Inc. (-1.09), greater than Arcus Biosciences, Inc. (-5.40), greater than TFF Pharmaceuticals, Inc. (-0.02), greater than INmune Bio, Inc. (-2.23), greater than Anebulo Pharmaceuticals, Inc. (-4.09), less than Abcam plc (578.45), greater than AN2 Therapeutics, Inc. (-0.69), greater than 89bio, Inc. (-2.96), greater than Madrigal Pharmaceuticals, Inc. (-13.03), greater than Pliant Therapeutics, Inc. (-4.02), greater than Arcellx, Inc. (-102.24), greater than Stoke Therapeutics, Inc. (-6.20), greater than Protalix BioTherapeutics, Inc. (-13.25), greater than Cidara Therapeutics, Inc. (-1.26), greater than Akebia Therapeutics, Inc. (-8.46), greater than X4 Pharmaceuticals, Inc. (-6.92), greater than Seres Therapeutics, Inc. (-5.78), greater than Vaxart, Inc. (-1.89), greater than iBio, Inc. (-0.88), greater than Tonix Pharmaceuticals Holding Corp. (-0.19), greater than BioCryst Pharmaceuticals, Inc. (-13.00),

Build a custom stock screener for ADMA Biologics, Inc. (ADMA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ADMA Biologics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

ADMA Biologics, Inc. (ADMA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like ADMA Biologics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.